Ricerca
Occhio al conflitto... di interesse! un’indagine su tre riviste mediche pediatriche
MIND THE CONFLICTS… OF INTEREST! SURVEY OF THREE PAEDIATRIC MEDICAL JOURNALS
DANIELE RADZIK
UO di Pediatria, Ospedale di Castelfranco Veneto (TV)
Maggio 2006 - pagg. 304 -308
Abstract
Conflicts of interest have often conditioned man’s behaviour since ancient times. In the medical field, the most evident aspect of such conflicts are the financial relations possibly connecting pharmaceutical industries to doctors. This circumstance may impair not only practitioners’ independence but also uprightness of scientific research and reliability of published trials. To avoid this, some leading general medical journals have recently taken a disclosure from the Authors of researches to declare explicitly whether a potential conflict of interest exist or not.
In order to verify if a similar precaution is being taken also in the paediatric field, we have looked into all editorials, original works and letters published in the course of the last year in three scientific international paediatric journals.
Parole chiave
Suggerite dall'AI
Classificazione MeSH
Bibliografia
1. Brioschi CA. Breve storia della corruzione,
dall’antichità ai giorni nostri. Edizioni Tea,
2004.
2. Thompson DF. Understanding financial conflict of interest. N Engl J Med 1993;329: 573-6.
3. Maddox J. Conflict of interest declared. Nature 1992;360:205.
4. Moynihan R. Who pays for the pizza? Redefining the relationships between doctors and drug companies. 1: Entanglement. BMJ 2003; 326:1189-92.
5. Lexchin J. What information do physicians receive from pharmaceutical representatives? Can Fam Physician 1997;43:941-5.
6. Bekelman J, Li Y, Gross G. Scope and impact of financial conflicts of interest in biomedical research. JAMA 2003;289:454-65.
7. Dana J, Loewenstein G. A social science perspective on gifts to physicians from industry. JAMA 2003;290:252-5.
8. Wazana A. Physicians and the pharmaceutical industry: is gift ever just a gift? JAMA 2000;283:373-80.
9. McKinney W, Shiedermayer D, Lurie N, Simpson D, Goodman J, Rich E. Attitudes of internal medicine faculty and residents toward professional interaction with pharmaceutical sales representatives. JAMA 1990; 264:1693-7.
10. Bollettino Italiano Farmaci 2001;4:145-9.
11. Kahn JO. Evaluation of HIV-1 immunogen, an immunologic modifier, administered to patients infected with HIV having 300 to 549X106/L CD4 cell counts: a randomized controlled trial. JAMA 2000;284:2193-202.
12. Blumenthal D. Withholding research results in academic life science evidence from a national survey of faculty. JAMA 1997;277: 1224-8.
13. Henderson L. More AMCs finding growth from reform. Center Watch 2000;1:10-3.
14. Davidoff F. Sponsorship, authorship and accountability. N Engl J Med 2001;345:825-7.
15. Djulbegovic B, Lacevic M, Cantor A. The uncertainty principle and industry-sponsored research. Lancet 2000;356:635-8.
16. Cho MK, Bero LA. The quality of drug studies published in symposium proceedings. Ann Intern Med 1996;124:485-9.
17. Lexchin J, Bero LA, Djulbegovic B, Clark O. Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ 2003;326:1167-70.
18. Safer DJ. Design and reporting modifications in industry-sponsored comparative psychopharmacology trials. J Nerv Ment Dis 2002:190;190:583-92.
19. Johansen HK, Gotzsche PC. Problems in the design and reporting of trials of antifungal agents encountered during meta-analysis. JAMA 1999;282:1752-9.
20. Rothman K, Michels K. The continuing unethical use of placebo controls. N Engl J Med 1994;331:394-8.
21. Bekelman JE, Li Yan, Gross CP. Scope and impact of financial conflicts of interest in biomedical research. JAMA 2003;289:454-65.
22. Eichenwald K, Kolata G. Drug trials hide conflicts for doctors. New York Times. May 16, 1999:A1.
23. Eichenwald K, Kolata G. A doctor’s drug trial turns into fraud. New York Times, May 17,1999:A1.
24. Angell M. Disclosure of authors’ conflicts of interest: a follow-up. N Engl J Med 2000; 342:586-7.
25. Hussain A, Smith R. Declaring financial competing interests: survey of five general medical journals. BMJ 2001;323:263-4.
26. Smith R. Conflitto di interessi in medicina e nelle riviste scientifiche. Focus Bollettino di farmacovigilanza. Novembre 2002 http:// www.farmacovigilanza.org/focus/200211.
27. Smith R. Medical Journals and pharmaceutical companies: uneasy bedfellows. BMJ 2003;326:137.
28. Morin K, Rakatansky H, Riddick Jr F. Managing conflict of interest in the conduct of clinical trials. JAMA 2002;287:78-84.
29. De Angelis CD, Drazen JM, Frizelle FA, Haug C, Hoey J, Horton R. Is this clinical trial fully registered? A statement from the International Committee of Medical Journal Editors. CMAJ 2005;172(13):1700-2.
30. De Angelis C, Drazen JM, Frizelle FA, Haug C, Hoey J, Horton R. Clinical trial registration: a statement from the International Committee of Medical Journal Editors. N Engl J Med 2004;351:1250-1.
31. Abbasi K. Compulsory registration of clinical trials. BMJ 2004;329:637-8.
32. Bonati M, Pandolfini C. DEC.net: il primo registro di studi clinici pediatrici. Medico e Bambino 2004;5:281-2.
33. Bonati M, Pandolfini C. Pediatric clinical trials registry. CMAJ 2005;172(9):1159
34. Editorial. Why should clinical trials be registered? CMAJ 2005;172(13):1653.
35. Marchetti F, Lazzerini M. La registrazione degli studi clinici: una garanzia a tutela dei pazienti? Medico e Bambino 2005;6:348.
36. WHO technical consultation on clinical trial registration standards meeting 27 April 2005; Geneva, Switzerland. http://www.who. int/ictrp/news/ictrp_sag_meeting_april2005_ conclusions.pdf.
37. Moher D, Schullz KF, Altman DG. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials. Lancet 2001; 357:1191-4.
38. Moynihan R. Who pays for the pizza? Redefining the relationships between doctors and drug companies. 2: Disentanglement. BMJ 2003;326:1193-6.
2. Thompson DF. Understanding financial conflict of interest. N Engl J Med 1993;329: 573-6.
3. Maddox J. Conflict of interest declared. Nature 1992;360:205.
4. Moynihan R. Who pays for the pizza? Redefining the relationships between doctors and drug companies. 1: Entanglement. BMJ 2003; 326:1189-92.
5. Lexchin J. What information do physicians receive from pharmaceutical representatives? Can Fam Physician 1997;43:941-5.
6. Bekelman J, Li Y, Gross G. Scope and impact of financial conflicts of interest in biomedical research. JAMA 2003;289:454-65.
7. Dana J, Loewenstein G. A social science perspective on gifts to physicians from industry. JAMA 2003;290:252-5.
8. Wazana A. Physicians and the pharmaceutical industry: is gift ever just a gift? JAMA 2000;283:373-80.
9. McKinney W, Shiedermayer D, Lurie N, Simpson D, Goodman J, Rich E. Attitudes of internal medicine faculty and residents toward professional interaction with pharmaceutical sales representatives. JAMA 1990; 264:1693-7.
10. Bollettino Italiano Farmaci 2001;4:145-9.
11. Kahn JO. Evaluation of HIV-1 immunogen, an immunologic modifier, administered to patients infected with HIV having 300 to 549X106/L CD4 cell counts: a randomized controlled trial. JAMA 2000;284:2193-202.
12. Blumenthal D. Withholding research results in academic life science evidence from a national survey of faculty. JAMA 1997;277: 1224-8.
13. Henderson L. More AMCs finding growth from reform. Center Watch 2000;1:10-3.
14. Davidoff F. Sponsorship, authorship and accountability. N Engl J Med 2001;345:825-7.
15. Djulbegovic B, Lacevic M, Cantor A. The uncertainty principle and industry-sponsored research. Lancet 2000;356:635-8.
16. Cho MK, Bero LA. The quality of drug studies published in symposium proceedings. Ann Intern Med 1996;124:485-9.
17. Lexchin J, Bero LA, Djulbegovic B, Clark O. Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ 2003;326:1167-70.
18. Safer DJ. Design and reporting modifications in industry-sponsored comparative psychopharmacology trials. J Nerv Ment Dis 2002:190;190:583-92.
19. Johansen HK, Gotzsche PC. Problems in the design and reporting of trials of antifungal agents encountered during meta-analysis. JAMA 1999;282:1752-9.
20. Rothman K, Michels K. The continuing unethical use of placebo controls. N Engl J Med 1994;331:394-8.
21. Bekelman JE, Li Yan, Gross CP. Scope and impact of financial conflicts of interest in biomedical research. JAMA 2003;289:454-65.
22. Eichenwald K, Kolata G. Drug trials hide conflicts for doctors. New York Times. May 16, 1999:A1.
23. Eichenwald K, Kolata G. A doctor’s drug trial turns into fraud. New York Times, May 17,1999:A1.
24. Angell M. Disclosure of authors’ conflicts of interest: a follow-up. N Engl J Med 2000; 342:586-7.
25. Hussain A, Smith R. Declaring financial competing interests: survey of five general medical journals. BMJ 2001;323:263-4.
26. Smith R. Conflitto di interessi in medicina e nelle riviste scientifiche. Focus Bollettino di farmacovigilanza. Novembre 2002 http:// www.farmacovigilanza.org/focus/200211.
27. Smith R. Medical Journals and pharmaceutical companies: uneasy bedfellows. BMJ 2003;326:137.
28. Morin K, Rakatansky H, Riddick Jr F. Managing conflict of interest in the conduct of clinical trials. JAMA 2002;287:78-84.
29. De Angelis CD, Drazen JM, Frizelle FA, Haug C, Hoey J, Horton R. Is this clinical trial fully registered? A statement from the International Committee of Medical Journal Editors. CMAJ 2005;172(13):1700-2.
30. De Angelis C, Drazen JM, Frizelle FA, Haug C, Hoey J, Horton R. Clinical trial registration: a statement from the International Committee of Medical Journal Editors. N Engl J Med 2004;351:1250-1.
31. Abbasi K. Compulsory registration of clinical trials. BMJ 2004;329:637-8.
32. Bonati M, Pandolfini C. DEC.net: il primo registro di studi clinici pediatrici. Medico e Bambino 2004;5:281-2.
33. Bonati M, Pandolfini C. Pediatric clinical trials registry. CMAJ 2005;172(9):1159
34. Editorial. Why should clinical trials be registered? CMAJ 2005;172(13):1653.
35. Marchetti F, Lazzerini M. La registrazione degli studi clinici: una garanzia a tutela dei pazienti? Medico e Bambino 2005;6:348.
36. WHO technical consultation on clinical trial registration standards meeting 27 April 2005; Geneva, Switzerland. http://www.who. int/ictrp/news/ictrp_sag_meeting_april2005_ conclusions.pdf.
37. Moher D, Schullz KF, Altman DG. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials. Lancet 2001; 357:1191-4.
38. Moynihan R. Who pays for the pizza? Redefining the relationships between doctors and drug companies. 2: Disentanglement. BMJ 2003;326:1193-6.
Corrispondenza: dradzik@tiscali.it